EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Schizophrenia and Glutathione: A Challenging Story

Barbara Carletti, Nerisa Banaj iD, Fabrizio Piras, Paola Bossù iD

Journal of Personalized Medicine · 25.10.2023 · 13 (11) · 1526

DOI: 10.3390/jpm13111526 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 25.10.2023. Verfasst von Barbara Carletti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuropsychiatry, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome,…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Schizophrenia (SZ) is a devastating mental illness with a complex and heterogeneous clinical state. Several conditions like symptoms, stage and severity of the disease are only some of the variables that have to be considered to define the disorder and its phenotypes. SZ pathophysiology is still unclear, and the diagnosis is currently relegated to the analysis of clinical symptoms; therefore, the search for biomarkers with diagnostic relevance is a major challenge in the field, especially in the era of personalized medicine. Though the mechanisms implicated in SZ are not fully understood, some processes are beginning to be elucidated. Oxidative stress, and in particular glutathione (GSH) dysregulation, has been demonstrated to play a crucial role in SZ pathophysiology. In fact, glutathione is a leading actor of oxidative-stress-mediated damage in SZ and appears to reflect the heterogeneity of the disease. The literature reports differing results regarding the levels of glutathione in SZ patients. However, each GSH state may be a sign of specific symptoms or groups of symptoms, candidating glutathione as a biomarker useful for discriminating SZ phenotypes. Here, we summarize the literature about the levels of glutathione in SZ and analyze the role of this molecule and its potential use as a biomarker.

Schlagwörter

Stichwörter der Autor:innen

biomarkerglutathioneneurodegenerationoxidative stressschizophrenia

Autor:innen und Institutionen

  • Laboratory of Neuropsychiatry, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179 Rome, Italy.
  • Laboratory of Experimental Neuropsychobiology, Clinical Neuroscience and Neurorehabilitation Department, IRCCS Santa Lucia Foundation, Via del Fosso di Fiorano 64, 00143 Rome, Italy.

ORCID-Profile: Nerisa Banaj, Paola Bossù

Zitieren

APA

Carletti, B., Banaj, N., Piras, F., & Bossù, P. (2023). Schizophrenia and Glutathione: A Challenging Story. Journal of Personalized Medicine, 13(11), 1526. https://doi.org/10.3390/jpm13111526

Vancouver

Carletti B, Banaj N, Piras F, Bossù P. Schizophrenia and Glutathione: A Challenging Story. Journal of Personalized Medicine. 2023;13(11):1526. doi:10.3390/jpm13111526

BibTeX
@article{Carletti2023,
  author = {Carletti, Barbara and Banaj, Nerisa and Piras, Fabrizio and Bossù, Paola},
  title = {Schizophrenia and Glutathione: A Challenging Story},
  journal = {Journal of Personalized Medicine},
  year = {2023},
  volume = {13},
  number = {11},
  pages = {1526},
  doi = {10.3390/jpm13111526}
}
Kostenlos starten →